Area of research
Molecular Biology · Nephrology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Cardiovascular Function and Risk Factors, and Sarcoidosis and Beryllium Toxicity Research.
The Last Decade in Cardiac Amyloidosis
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
Cardiac Amyloidosis Due to Transthyretin Protein
Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis
Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis
Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis
Functional Status and Quality of Life in Light-Chain Amyloidosis
Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study
The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology
Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study
Whole Genome Association Study of the Plasma Metabolome Identifies Metabolites Linked to Cardiometabolic Disease in Black Individuals
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience
Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25‐year longitudinal study
Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization
Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging
Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy